Evidence map›Paper›PMID 30617925›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.

Carlota Moya-Alarcón, Almudena González-Domínguez, Susana Simon, Inés Pérez-Román, Antonio González-Martín, Eloisa Bayo-Lozano, Ana Beatriz Sánchez-Heras

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Cost-Effectiveness Analysis of Germline and SomaticAnnals of laboratory medicine · 2023
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carlota Moya-AlarcónAstraZeneca Farmaceutica Spain, 56, Serrano Galvache Street, Building Álamo, 28033, Madrid, Spain.
Almudena González-DomínguezWeber, 17, 5º, Moreto Street, 28014, Madrid, Spain. almudena.gonzalez@weber.org.es.ORCID http://orcid.org/0000-0002-3509-0961
Susana SimonAstraZeneca Farmaceutica Spain, 56, Serrano Galvache Street, Building Álamo, 28033, Madrid, Spain.
Inés Pérez-RománWeber, 17, 5º, Moreto Street, 28014, Madrid, Spain.
Antonio González-MartínClínica Universidad de Navarra, 1, Marquesado de Santa Marta Street, 28027, Madrid, Spain.
Eloisa Bayo-LozanoPlan Integral de Oncología de Andalucía, Servicio Andaluz de Salud, Hospital Juan Ramón Jiménez, Ronda Exterior Norte, 21005, Huelva, Spain.
Ana Beatriz Sánchez-HerasGrupo Español de Investigación en Cáncer de Ovario (GEICO), 151, Santa Engracia Street, Floor 5, Office 3, 28003, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGermline mutations in BRCA1 and/or BRCA2 genes (gBRCA1/2m) are associated with an increased risk of breast cancer (BC) and ovarian cancer (OC). The aim of this study was to estimate the efficiency of providing germline BRCA1/2 testing to high-grade epithelial ovarian cancer (HGEOC) patients without family history of OC or BC and the subsequent testing and management of their relatives with gBRCA1/2m in Spain. METHODS/PATIENTS: Incident HGEOC patients without family history of OC or BC who were gBRCA1/2m carriers and their relatives were simulated in a 50-year time horizon. The study compared two scenarios: BRCA1/2 testing vs no testing, using the perspective of the Spanish National Health Service. Cancer risk among gBRCA1/2m carriers was estimated based on their age and whether they had undergone risk-reducing surgeries. Direct healthcare costs and utilities of patients who developed EOC and BC were also included. A probabilistic sensitivity analysis (PSA) with 5 thousand simulations was developed considering ± 25% of the base-case value.

resultsThe BRCA1/2-testing scenario amounted to €13,437,897.43 while the no-testing scenario amounted to €12,053,291.17. It was estimated that the screening test improved the quality of life among the patients' relatives by 43.8 quality-adjusted life years (QALYs). The incremental cost-utility ratio (ICUR) was €31,621.33/QALY in the base case. The PSA showed that 89.12% of the simulations were below the €50,000/QALY threshold.

conclusionProviding this screening test to HGEOC patients and their relatives is cost-effective and it allows one to identify a target population with high risk of cancer to provide effective prevention strategies.

Indexed as

Cost-Benefit AnalysisGerm-Line MutationAdultBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCarcinoma, Ovarian EpithelialFemaleFollow-Up StudiesGenetic Predisposition to DiseaseGenetic TestingHealth Care CostsHumansMiddle AgedNeoplasm GradingPrognosisBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1 geneBRCA2 geneCancer screening testCost–utility analysisOvarian cancerQuality-adjusted life years

Identifiers

PMID30617925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.